Семейная фибрилляция предсердий как полигенное заболевание со структурными аномалиями сердца: оценка генетического риска и возможности генной терапии
https://doi.org/10.35336/VA-1184
Аннотация
Рассматривается распространенность семейной фибрилляции предсердий (ФП) в общей популяции и в структуре ФП, а также анализируются генетические предикторы ФП и патогенетические механизмы ремоделирования предсердий. Обсуждается оценка генетического риска возникновения ФП, прогнозирования ее исходов и эффективности терапии ФП, а также перспективы генной терапии ФП.
Об авторе
Б. Г. Искендеров
Пензенский институт усовершенствования врачей - филиал ФГБОУ ДПО «Российская медицинская
академия непрерывного профессионального образования» МЗ РФ
Россия
Россия
Бахрам Гусейнович Искендеров
Пенза, ул. Стасова, 8А
Список литературы
1. Staerk L, Sherer JA, Ko D, et al. Atrial fibrillation: epidemiology, pathophysiology, and clinical outcomes. Circ Res. 2017;120(9): 1501-17. https://doi.org/10.1161/CIRCRESAHA.117.309732.
2. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021; 42(5):373-498. https://doi.org/10.1093/eurheartj/ehaa612.
3. Ревишвили АШ, Шляхто ЕВ, Попов СВ, и др. Клинические рекомендации по проведению электрофизиологических исследований, катетерной абляции и применению имплантируемых антиаритмических устройств. М., 2017:156-76. Available from: vnoa.ru/literature.
4. Andersen JH, Andreasen L, Olesen MS. Atrial fibrillation - a complex polygenetic disease. Eur J Human Genetics. 2021;29(7): 1051-60. https://doi.org/10.1038/s41431020-00784-8.
5. Christophersen IE, Rienstra M, Roselli C, et al. Largescale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation. Nat Genet. 2017;49(6): 946-52. https://doi.org/10.1038/ng.3843.
6. Manoharan A, Sambandam R, Ballambattu VB. Genetics of atrial fibrillation - an update of recent findings. Mol Biol Rep. 2022;49(8): 8121-9. https://doi.org/10.1007/s11033-022-07420-2.
7. Голухова ЕЗ, Жолбаева АЗ, Аракелян МГ, и др. Генетические аспекты развития идиопатической фибрилляции предсердий у больных без структурных сердечных аномалий. Вестник РАМН. 2019; 74(4): 245-52. https://doi.org/10.15690/vramn1120.
8. Weng LC, Preis SR, Hulme OL, et al. Genetic predisposition, clinical risk factor burden, and lifetime risk of atrial fibrillation. Circulation. 2018;137(10): 1027-38. https://doi.org/10.1161/CIRCULATIONAHA.117.031431.
9. Waldmann V, Laredo M, Abadir S, et al. Atrial fibrillation in adults with congenital heart disease. Int J Cardiol. 2019;287: 148-54. https://doi.org/10.1016/j.ijcard.2019.01.079.
10. Аракелян МГ, Бокерия ЛА, Васильева ЕЮ, и др. Фибрилляция и трепетание предсердий. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(7):4594. https://doi.org/10.15829/1560-4071-2021-4594
11. Lozano-Velasco E, Franco D, Aranega A, et al. Genetics and epigenetics of atrial fibrillation. Int J Mol Sci. 2020; 21(16): 5717. https://doi.org/10.3390/ijms21165717.
12. Tucker NR, Clauss S, Ellinor PT. Common variation in atrial fibrillation: Navigating the path from genetic association to mechanism. Cardiovasc Res. 2016;109(4): 493501. https://doi.org/10.1093/cvr/cvv283.
13. Young LJ, Antwi-Boasiako S, Ferrall J, et al. Genetic and non-genetic risk factors associated with atrial fibrillation. Life Sci. 2022;299: 120529. https://doi.org/10.1016/j.lfs.2022.120529.
14. Ragab AAY, Sitorus GDS, Brundel BBJJM, et al. The genetic puzzle of familial atrial fibrillation. Front Cardiovasc Med. 2020;7: 14. https://doi.org/10.3389/fcvm.2020.00014.
15. Gundlund A, Fosbol EL, Kim S, et al. Family history of atrial fibrillation is associated with earlier-onset and more symptomatic atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Am Heart J. 2016;175: 28-35. https://doi.org/10.1016/j.ahj.2016.01.020.
16. Доступно из: https://medlineplus.gov/genetics/condition/familial-atrial-fibrillation.
17. Roselli C, Rienstra M, Ellinor PT. Genetics of atrial fibrillation in 2020. GWAS, genome sequencing, polygenic risk, and beyond. Circ Res. 2020;127(1): 21-33. https://doi.org/10.1161/CIRCRESAHA.120.316575.
18. Nielsen JB, Fritsche LG, Zhou W, et al. Genome-wide study of atrial fibrillation identifies seven risk loci and highlights biological pathways and regulatory elements involved in cardiac development. Am J Hum Genet. 2018;102(1): 103-15.
19. Syeda F, Holmes AP, Yu TY, et al. PITX2 modulates atrial membrane potential and the antiarrhythmic effects of sodium-channel blockers. JACC. 2016;68: 1881-94. https://doi.org/10.1016/j.jacc.2016.07.766.
20. Kany S, Reissmann B, Metzner A, et al. Genetics of atrial fibrillation - practical applications for clinical management: if not now, when and how? Cardiovasc Res. 2021;117: 1718-31. https://doi.org/10.1093/cvr/cvab153.
21. Thorolfsdottir RB, Sveinbjornsson G, Sulem P, et al. Coding variants in RPL3L and MYZAP increase risk of atrial fibrillation. Commun Biol. 2018;1: 68. https://doi.org/10.1038/s42003-018-0068-9.
22. Choi SH, Weng L-C, Roselli C, et al. Association between titin loss-of-function variants and early-onset atrial fibrillation. JAMA. 2018;320: 2354-64. https://doi.org/10.1001/jama.2018.18179.
23. Zhou M, Liao Y, Tu X. The role of transcription factors in atrial fibrillation. J Thorac Dis. 2015;7(2): 152-8. https://doi.org/10.3978/j.issn.2072-1439.2015.01.2.
24. Shoemaker MB, Andreas B, Steven AL, et al. Common genetic variants and response to atrial fibrillation ablation. Circ Arrhythm Electrophysiol. 2015;8: 296-302. https://doi.org/10.1161/CIRCEP.114.001909.
25. Husser D, Ueberham L, Hindricks G, et al. Rare variants in genes encoding the cardiac sodium channel and associated compounds and their impact on outcome of catheter ablation of atrial fibrillation. PLos One. 2017;12: e0183690.
26. Giudicessi JR, Wilde AAM, Ackerman MJ. The genetic architecture of long QT syndrome: A critical reappraisal. Trends Cardiovasc Med. 2018;28(7): 453-64. https://doi.org/10.1016/j.tcm.2018.03.003.
27. Greiser M. Calcium signaling silencing in atrial fibrillation. J Physiol. 2017;595(12): 4009-17. https://doi.org/10.1113/JP2730454009-17.
28. Сапельников ОВ, Куликов АА, Фаворова ОО, и др. Значение генетических, эпигенетических факторов и факторов транскрипции в фибрилляции предсердий. Рациональная Фармакотерапия в Кардиологии. 2019;15(3): 407-15. https://doi.org/10.20996/1819-6446-2019-15-3-407-15.
29. Вайханская ТГ, Курушко ТВ, Персидских ЮА, и др. Предсердная кардиомиопатия - новая концепция с давней историей. Российский кардиологический журнал. 2020;25(11): 3942. https://doi.org/10.15829/1560-4071-2020-3942.
30. Понасенко АВ, Синицкий МЮ, Хуторная МВ. Молекулярно-генетические маркеры фибрилляции предсердий. Бюллетень сибирской медицины. 2020;19(1):180-9. https://doi.org/10.20538/1682-03632020-1-180-189.
31. Guo YH, Yang YQ. Atrial fibrillation: focus on myocardial connexins and gap junctions. Biology (Basel). 2022;11(4): 489. https://doi.org/10.3390/biology11040489.
32. Wang Q, Hu X, Li S, et al. Association of the angiotensinogen M235T polymorphism with recurrence after catheter ablation of acquired atrial fibrillation. J Renin Angiotensin Aldosterone Syst. 2015;16: 888-97. https://doi.org/10.1177/1470320315594315.
33. Lee S-P, Ashley EA, Homburger J, et al. Incident atrial fibrillation is associated with MYH7 sarcomeric gene variation in hypertrophic cardiomyopathy. Circ Heart Fail. 2018;11: e005191.
34. Vad OB, Paludan-Müller C, Ahlberg G, et al. Loss-offunction variants in cytoskeletal genes are associated with early-onset atrial fibrillation. J Clin Med. 2020;9(2): 37283. https://doi.org/10.3390/jcm9020372.
35. Cochet H, Dubois R, Yamashita S, et al. Relationship between fibrosis detected on late gadolinium-enhanced cardiac magnetic resonance and re-entrant activity assessed with electrocardiographic imaging in human persistent atrial fibrillation. JACC Clin Electrophysiol. 2018;4: 1729. https://doi.org/10.1016/j.jacep.2017.07.019.
36. Ghaleb R, Anselmino M, Gaido L, et al. Prevalence and clinical significance of latent Brugada syndrome in atrial fibrillation patients below 45 years of age. Front Cardiovasc Med. 2020;7: 602536. https://doi.org/10.3389/fcvm.2020.602536.
37. Dobrev D, Dudley SC. Oxidative stress: a bystander or a causal contributor to atrial remodelling and fibrillation? Cardiovasc Res. 2021;117: 2291-3. https://doi.org/10.1093/cvr/cvab124.
38. Wilde AAM, Semsarian C, Márquez MF, et al. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/ Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases. Journal of Arrhythmia. 2022;38(4): 491553. https://doi.org/10.1002/joa3.12717
39. Lazarte J, Dron JS, McIntyre AD, et al. Evaluating polygenic risk scores in “lone” atrial fibrillation. CJC Open. 2021;3(6): 751-7. https://doi.org/10.1016/j.cjco.2021.02.001.
40. Khera AV, Chaffin M, Aragam KG, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018;50: 1219-24. https://doi.org/10.1038/s41588-0180183-z.
41. Pulit SL, Weng L-C, McArdle PF, et al. Atrial fibrillation genetic risk differentiates cardioembolic stroke from other stroke subtypes. Neurol Genet. 2018;4: e293. https://doi.org/10.1212/NXG.0000000000000293.
42. Hucker WJ, Hanley A, Ellinor PT. Improving atrial fibrillation therapy: Is there a gene for that? JACC. 2017;69(16): 2088-95. https://doi.org/10.1016/j.jacc.2017.02.043.
43. Trivedi A, Hoffman J, Arora R. Gene therapy for atrial fibrillation - how close to clinical implementation? Int J Cardiol. 2019;296: 177-83. https://doi.org/10.1016/j.ijcard.2019.07.057.
44. Yoo S, Geist GE, Pfenniger A, et al. Recent advances in gene therapy for atrial fibrillation. J Cardiovasc Electrophysiol. 2021;32(10): 2854-64. https://doi.org/10.1111/jce.15116.
45. Hu H, Wang L, Li H, et al. Long-term amelioration of an early-onset familial atrial fibrillation model with AAV-mediated in vivo gene therapy. Fundamental Research. 2022;6(2): 829-35. https://doi.org/10.1016/j.fmre.2022.05.002.
46. Wu H, Xu J, Chen S, et al. Association of SCN10A polymorphisms with the recurrence of atrial fibrillation after catheter ablation in a Chinese Han population. Sci Rep. 2017;7: 44003. https://doi.org/10.1038/srep44003.
47. Ravens U. Atrial-selective K+ channel blockers: potential antiarrhythmic drugs in atrial fibrillation? Can J Physiol Pharmacol. 2017;95(11): 1313-8. https://doi.org/10.1139/cjpp-2017-0024.
48. Pfenniger A, Geist GE, Arora R. Autonomic dysfunction and neurohormonal disorders in atrial fibrillation. Card Electrophysiol Clin. 2021;13(1): 183-90. https://doi.org/10.1016/j.ccep.2020.11.012.
49. Kunamalla A, Ng J, Parini V, et al. Constitutive expression of a dominant negative TGF-β type II receptor in the posterior left atrium leads to beneficial remodeling of atrial fibrillation substrate. Circ Res. 2016;119: 69-82. https://doi.org/10.1161/CIRCRESAHA.115.307878.
Рецензия
Для цитирования:
Искендеров Б.Г. Семейная фибрилляция предсердий как полигенное заболевание со структурными аномалиями сердца: оценка генетического риска и возможности генной терапии. Вестник аритмологии. 2023;30(3):e1-e10. https://doi.org/10.35336/VA-1184
For citation:
Iskenderov B.G. Familial atrial fibrillation as a polygenic disease with structural cardiac abnormalities: assessment of genetic risk and possibilities for gene therapy. Journal of Arrhythmology. 2023;30(3):e1-e10. https://doi.org/10.35336/VA-1184
Просмотров:
334
Послать статью по эл. почте 